Day: November 19, 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.130-95-0,Quinine,as a common compound, the synthetic route is as follows.

General procedure: The alkaloid (12.3 mmol, 1 eq.) and the appropriate substituted benzylic halide derivative(12.3 mmol, 1 eq.) were dissolved in THF (40 mL) with addition of a trace of NaI. The mixture washeated to reflux overnight and then cooled and stirred at ambient temperature for 1 h. In most cases theproduct precipitated as an off-white solid, but where this was not the case and the mixture containedonly a small amount of solid or no solid at all, then diethyl ether (20 mL) was added dropwise.The solid was removed via filtration and washed with THF (50 mL) or ether:THF, (1:1, v/v, 50 mL)and was dried under reduced pressure at 40 C. Where the solid formed was not a fine powder it was then taken up in DCM and this solution was then added dropwise to rapidly stirring ether (100 mL).This usually gives a finely divided solid that could be filtered and dried. (Note: The cinchonine derivedPTCs are usually very insoluble. The quinidine derived PTCs are often completely soluble at the endof the reaction.) The di(t-butyl)benzyl PTC was prepared according to the standard procedure aboveand was filtered directly from the reaction mixture., 130-95-0

130-95-0 Quinine 3034034, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen; Molecules; vol. 23; 7; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

168646-54-6, 5,6-Diamino-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

168646-54-6, 0.33 g of 4,4′-dinitrobenzil (1.0 mmol) and 0.21 g of 5,6-diamine-1,10-phenanthroline (1.0 mmol) were put into a 100 mL single-necked flask, 30 mL of glacial acetic acid was added, Stirring, reaction under nitrogen 2h. After the reaction was completed, the solvent was removed by rotary evaporation and spin-dried. An appropriate amount of dichloromethane was added and the mixture was stirred for 10 min. Filtration, rotary evaporation of the solvent. The resulting solid was recrystallized from absolute ethanol, suction filtered and dried in vacuo to give 0.352 g of pale yellow crystals, The yield is 78.6percent. The reaction is:

The synthetic route of 168646-54-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Jiangnan University; Zheng Changge; Xie Chen; Li Mingyue; (8 pag.)CN105884833; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Synthesis of 2,9-bis(4-(benzo[d]oxazol-2-yl)phenyl)-4,7-diphenyl-1,10-phenanthrolineTo a three-necked flask of 250 ml, 6.03 g (22 mmol) of 2-(4-bromophenyl)benzo[d]oxazole and 70 ml of THF were charged, then 13.8 ml (22 mmol) n-butyllithium (1.6M in Hexane solution) was dropped under stirring at -78 C. in a nitrogen atmosphere. The mixture was stirred for one hour at -78 C., and a solution of 1.86 g (5.6 mmol) of 4,7-diphenyl-1,10-phenanthroline in 30 ml THF was dropped. Then the mixture was stirred at room temperature for overnight and was added with water. The organic layer was extracted with Dichloromathane and dried with anhydrous magnesium sulfate, the solvent was removed by rotary evaporation. The product was purified by column chromatography on alumina using Dichloromethane/Hexane as eluent and dried in vacuo, obtaining white powder compound 2.10 g (yield of 52.14%). MS (m/z, FAB+) 718.8.

1662-01-7, The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Yen, Feng Wen; US2008/265746; (2008); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

General procedure: The alkaloid (12.3 mmol, 1 eq.) and the appropriate substituted benzylic halide derivative(12.3 mmol, 1 eq.) were dissolved in THF (40 mL) with addition of a trace of NaI. The mixture washeated to reflux overnight and then cooled and stirred at ambient temperature for 1 h. In most cases theproduct precipitated as an off-white solid, but where this was not the case and the mixture containedonly a small amount of solid or no solid at all, then diethyl ether (20 mL) was added dropwise.The solid was removed via filtration and washed with THF (50 mL) or ether:THF, (1:1, v/v, 50 mL)and was dried under reduced pressure at 40 C. Where the solid formed was not a fine powder it was then taken up in DCM and this solution was then added dropwise to rapidly stirring ether (100 mL).This usually gives a finely divided solid that could be filtered and dried. (Note: The cinchonine derivedPTCs are usually very insoluble. The quinidine derived PTCs are often completely soluble at the endof the reaction.) The di(t-butyl)benzyl PTC was prepared according to the standard procedure aboveand was filtered directly from the reaction mixture.

485-71-2, 485-71-2 Cinchonidine 101744, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen; Molecules; vol. 23; 7; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

To a solution of 2 (194 mg, 0.09 mmol) and 3 ( 52mg, 0.09ml) in acetonitrile (8ml), HTBU ( 34mg, 0.09 mmol) wa added followed by triethylamine ( 25 muL, 0.18mmol) at RT. the reaction was stirred for 18 h. The reaction was diluted with 30 mL dichloromethane and washed 0.1 N HCl(30 mL), 10% NaHCO3 (30 mL), brine (30 mL), then dried over MgSO4, and concentrated. The crudeproduct was purified by column chromatography (DCM:MeOH = 97:5 DCM:MeOH = 85:15) togive 4 (Figure 7) as a foam (105 mg, 43%). 1H-NMR (400 MHz, CDCl3): delta 3.68-3.47 (m, 104H,CH2OCH2CH2OCH2CH2OCH2, C3N3-NHCH2CH2CH2O , Dota-CONHCH2CH2CH2O), 3.22-3.18(br m, 8H, BocNHCH2), 1.84-1.72 (m, 28H, OCH2CH2CH2), 1.46 (s, 9H), 1.45 (s, 9H), 1.42 (s, 45H);13C-NMR (100 MHz, CDCl3) delta 176.6 (DOTA-OCOtBu), 174.4 (DOTA-OCOtBu), 172.3 (DOTA-OCOtBu),not found (C3N3), 156.0 (NHCOtBu), 81.7 (DOTA-OC(CH3)3), 78.7 (C(CH3)3), 70.47 (OCH2CH2O),70.21 (OCH2CH2O), 70.17 (OCH2CH2O), 70.10 (OCH2CH2O), 69.42 (CH2CH2CH2O), 69.02(CH2CH2CH2O), 57.5 (DOTA), 56.2 (DOTA), 55.6 (DOTA), 53.5 (DOTA), 41.9 (NH2CH2CH2CH2O),38.5 (CH2CH2CH2O), 38.4 (CH2CH2CH2O), 29.6 (NH2CH2CH2CH2O), 29.3 (NH2CH2CH2CH2O),28.4 (C(CH3)3), 27.94 (DOTA-OC(CH3)3), 27.87 (DOTA-OC(CH3)3); MS (ESI-TOF) calcd. forC127H242N27O36 2721.7936, found 2721.8117 [M + H]+. Spectra appear in the Supplementary Materials:Figures S11-S13

137076-54-1, As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Article; Lee, Changsuk; Ji, Kun; Simanek, Eric E.; Molecules; vol. 21; 3; (2016);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4730-54-5

Example 10Synthesis of l,4,7-tris{[6′-ethoxycarbonyl-4′-(4″-methoxycarbonyl-l ‘-methylpyrrol- 5 ‘ ‘ -yl)pyridine-2 ‘ -yljmethyl} – 1 ,4,7-triazacyclononane (9); A mixture of compound 9 (35 mg, 0.104 mmol), 1,4,7-triazacyclononane (4.4 mg, 0.034), potassium carbonate (29 mg, 0.208 mmol) and DMF (2 ml) was stirred overnight at room temperature. The reaction mixture was filtered, evaporated to dryness and the product purified by preparative TLC (15 % EtOH/CH2Cl2 + 1% TEA). Yield was 20 mg (57 %).

The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; WALLAC OY; KETOLA, Janne; HOVINEN, Jari; WO2010/55207; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23195-62-2,2-(1H-1,2,4-Triazol-3-yl)pyridine,as a common compound, the synthetic route is as follows.

A BMes2-functionalized phenyl-triazole (3a) ligand (0.10 mmol) and [PtMe2(u-SMe2)]2 (0.032 g, 0.055 mmol) were added to a 20 mL screw-cap vial with of acetone (5 mL). The resulting mixture was heated to and maintained at 75 C for 2 hours. Then, a 0.10 M solution of TsOH in THF (1 mL) was added. The resulting solution was stirred for 1 hour. Next, 0.1 M solution of 2-(1 H-1 ,2,4-triazol-3-yl)pyridine in methanol (2 mL) was added and the mixture was stirred overnight. The solvent was then removed under reduced pressure. The crude product was dissolved in methanol and purified on TLC plate using acetone as the eluent.

23195-62-2, The synthetic route of 23195-62-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; QUEEN’S UNIVERSITY AT KINGSTON; WANG, Suning; HUDSON, Zachary, M.; WANG, Xiang; WO2014/138912; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.153-94-6,H-D-Trp-OH,as a common compound, the synthetic route is as follows.

General procedure: 5-Bromothiophene-2-sulfonylchloride (1g, 4.43 mmol) was added to a solution of the appropriate non-natural commercial amino acid (4.43 mmol) in H2O (4.43 mL) and dioxane (13.3 mL) containing Et3N (1.24 mL, 8.86 mmol). The mixture was stirred at room temperature overnight, the dioxane was evaporated and the residue was treated with EtOAc and washed with HCl 1 N and brine. Organic layers were then collected, dried over Na2SO4, and evaporated in vacuo.

153-94-6, As the paragraph descriping shows that 153-94-6 is playing an increasingly important role.

Reference£º
Article; Nuti, Elisa; Casalini, Francesca; Santamaria, Salvatore; Gabelloni, Pamela; Bendinelli, Sara; Da Pozzo, Eleonora; Costa, Barbara; Marinelli, Luciana; La Pietra, Valeria; Novellino, Ettore; Margarida Bernardo; Fridman, Rafael; Da Settimo, Federico; Martini, Claudia; Rossello, Armando; European Journal of Medicinal Chemistry; vol. 46; 7; (2011); p. 2617 – 2629;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

40000-20-2, 5-Bromo-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,40000-20-2

Synthesis of Compound 57: The compound 57a (3.9 g, 15.0 mmol),Phenoxazine (2.9 g, 16 mmol),Tert-butylphosphine (0.35 g, 2 mmol),Palladium acetate (0.4 g, 1.8 mmol) and cesium carbonate (9.7 g, 30 mmol) were dissolved in toluene,Under a nitrogen atmosphere,The reaction was heated under reflux for 10 hours.The solvent was evaporated in vacuo,The remaining material was stirred with pentane,filter,Purification by silica gel column chromatography,To obtain solid compound 5, (3.7 g, 10.2 mmol),Yield 62percent.

The synthetic route of 40000-20-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Shanghai Tianma Organic Shine Display Co., Ltd.; Tianmawei Electronic Co., Ltd.; Wang Xiangcheng; Liu Ying; Ren Hongyang; He Wei; Liu Chen; (43 pag.)CN106831743; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

1,4,7-Triazatricyclo[5.2.1.0410]decane (Orthoamide) 0.5 mol 1,4,7-triazacyclononane, 64.3 g, 0.54 mol orthoformicacidtriethylester, 74.8 g, and 20 mmol p-toluolsulphonacid, 4 g, are heated to 150 C. The ethanol that is created and some of the esters are distilled off. After the reaction has been completed the orthoamide can be distilled off at a pressure of <80 mbar in the form of a bright yellow volatile oil (b.p. 350 K at 133 Pa), in agreement with literature (T. J. Atkins, J. Am. Chem. Soc., 102, 6365 (1980)). 4730-54-5, The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Unilever Home & Personal Care USA, division of Conopco, Inc.; US6646122; (2003); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI